gamma-aminobutyric acid has been researched along with Diabetes Mellitus, Type 2 in 59 studies
gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.
gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.
Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study suggests that the T/A combination treatment is as effective as gabapentin in the treatment of painful diabetic neuropathy in patients with Type 2 diabetes." | 9.14 | Comparison of the efficacy and safety of tramadol/acetaminophen combination therapy and gabapentin in the treatment of painful diabetic neuropathy. ( Baik, SH; Cha, BY; Kim, CH; Kim, DS; Ko, KS; Ko, SH; Kwon, HS; Lee, JH; Mok, JO; Noh, JH; Park, IB; Park, TS; Son, HS; Yu, JM, 2010) |
| "This study compared the efficacy and safety of tramadol/acetaminophen (T/A) and gabapentin in the management of painful diabetic neuropathy." | 9.14 | Comparison of the efficacy and safety of tramadol/acetaminophen combination therapy and gabapentin in the treatment of painful diabetic neuropathy. ( Baik, SH; Cha, BY; Kim, CH; Kim, DS; Ko, KS; Ko, SH; Kwon, HS; Lee, JH; Mok, JO; Noh, JH; Park, IB; Park, TS; Son, HS; Yu, JM, 2010) |
| "The role of gamma-aminobutyric acid (GABA) in attenuates insulin resistance (IR) in type 2 diabetic (T2D) patients and the reduction of the risk of IR in their offspring, and the function of GLUT4, IRS1 and Akt2 genes expression were investigated." | 8.02 | Gamma-aminobutyric acid attenuates insulin resistance in type 2 diabetic patients and reduces the risk of insulin resistance in their offspring. ( Rezazadeh, H; Sharifi, M; Sharifi, MR; Soltani, N, 2021) |
| " After six weeks of gabapentin treatment in 2400 mg daily dose a significant pain reduction was observed, assessed by means of SF-MPQ, VAS and PPI questionnaires." | 7.72 | [Gabapentin in the treatment of neuropathic pain in patients with type 2 diabetes mellitus]. ( Bilinska, M; Paradowski, B, 2003) |
| "Assessment of pain relief in type 2 diabetes mellitus patients with neuropathic pain treated with gabapentin at daily dose 2400 mg." | 7.72 | [Gabapentin in the treatment of neuropathic pain in patients with type 2 diabetes mellitus]. ( Bilinska, M; Paradowski, B, 2003) |
| "Obesity and type 2 diabetes have reached epidemic proportions; however, scarce information about how these metabolic syndromes influence brain energy and neurotransmitter homeostasis exist." | 5.36 | Obesity and type 2 diabetes in rats are associated with altered brain glycogen and amino-acid homeostasis. ( Benie, AJ; Bouman, SD; Schousboe, A; Sickmann, HM; Waagepetersen, HS, 2010) |
| "Glycogen levels were also lower in this region." | 5.36 | Obesity and type 2 diabetes in rats are associated with altered brain glycogen and amino-acid homeostasis. ( Benie, AJ; Bouman, SD; Schousboe, A; Sickmann, HM; Waagepetersen, HS, 2010) |
| "26 patients with type 2 diabetes mellitus and painful neuropathy were included into the study." | 5.32 | [Gabapentin in the treatment of neuropathic pain in patients with type 2 diabetes mellitus]. ( Bilinska, M; Paradowski, B, 2003) |
| "Assessment of pain relief in type 2 diabetes mellitus patients with neuropathic pain treated with gabapentin at daily dose 2400 mg." | 5.32 | [Gabapentin in the treatment of neuropathic pain in patients with type 2 diabetes mellitus]. ( Bilinska, M; Paradowski, B, 2003) |
| "This study compared the efficacy and safety of tramadol/acetaminophen (T/A) and gabapentin in the management of painful diabetic neuropathy." | 5.14 | Comparison of the efficacy and safety of tramadol/acetaminophen combination therapy and gabapentin in the treatment of painful diabetic neuropathy. ( Baik, SH; Cha, BY; Kim, CH; Kim, DS; Ko, KS; Ko, SH; Kwon, HS; Lee, JH; Mok, JO; Noh, JH; Park, IB; Park, TS; Son, HS; Yu, JM, 2010) |
| "This study suggests that the T/A combination treatment is as effective as gabapentin in the treatment of painful diabetic neuropathy in patients with Type 2 diabetes." | 5.14 | Comparison of the efficacy and safety of tramadol/acetaminophen combination therapy and gabapentin in the treatment of painful diabetic neuropathy. ( Baik, SH; Cha, BY; Kim, CH; Kim, DS; Ko, KS; Ko, SH; Kwon, HS; Lee, JH; Mok, JO; Noh, JH; Park, IB; Park, TS; Son, HS; Yu, JM, 2010) |
| " High-energy diet, saturated fats and trans-fats during perinatal period could suppress Delta(6) and Delta(5) desaturases both in the maternal and fetal tissues, resulting in a decrease in the concentrations of long-chain polyunsaturated fatty acids (LCPUFAs): arachidonic acid (AA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) that have a negative feedback control on inflammation." | 4.84 | Is metabolic syndrome X a disorder of the brain with the initiation of low-grade systemic inflammatory events during the perinatal period? ( Das, UN, 2007) |
| "The role of gamma-aminobutyric acid (GABA) in attenuates insulin resistance (IR) in type 2 diabetic (T2D) patients and the reduction of the risk of IR in their offspring, and the function of GLUT4, IRS1 and Akt2 genes expression were investigated." | 4.02 | Gamma-aminobutyric acid attenuates insulin resistance in type 2 diabetic patients and reduces the risk of insulin resistance in their offspring. ( Rezazadeh, H; Sharifi, M; Sharifi, MR; Soltani, N, 2021) |
| " After six weeks of gabapentin treatment in 2400 mg daily dose a significant pain reduction was observed, assessed by means of SF-MPQ, VAS and PPI questionnaires." | 3.72 | [Gabapentin in the treatment of neuropathic pain in patients with type 2 diabetes mellitus]. ( Bilinska, M; Paradowski, B, 2003) |
| "Assessment of pain relief in type 2 diabetes mellitus patients with neuropathic pain treated with gabapentin at daily dose 2400 mg." | 3.72 | [Gabapentin in the treatment of neuropathic pain in patients with type 2 diabetes mellitus]. ( Bilinska, M; Paradowski, B, 2003) |
| "Thirty patients with type 2 diabetes with peripheral neuropathy as assessed by a visual analog scale (VAS) and divided into two groups of 15 patients, treated for up to three months." | 3.30 | Effectiveness of oral clonidine and gabapentin on peripheral neuropathy in diabetic patients in southwestern Iran: a randomized clinical trial. ( Ahmadi, SA; Bagheri, S; Dolatkhah, H; Hassanzadeh, S; Majid Ahmadi, S; Moradishibany, I; Reisi, S, 2023) |
| " Safety assessments included adverse events (AEs), clinical laboratory tests, and electrocardiograms." | 2.79 | Efficacy and safety of mirogabalin (DS-5565) for the treatment of diabetic peripheral neuropathic pain: a randomized, double-blind, placebo- and active comparator-controlled, adaptive proof-of-concept phase 2 study. ( Feins, K; Hsu, C; Merante, D; Rosenstock, J; Sharma, U; Vinik, A, 2014) |
| " Pregabalin was well tolerated; somnolence (26%), dizziness (24%), peripheral oedema (13%) and weight gain (11%) were the most common adverse events and generally were reported as mild to moderate." | 2.76 | Efficacy and safety of pregabalin for treating neuropathic pain associated with diabetic peripheral neuropathy: a 14 week, randomized, double-blind, placebo-controlled trial. ( Arakawa, A; Baba, M; Satoh, J; Shoji, S; Suzuki, M; Yagihashi, S; Yoshiyama, T, 2011) |
| "Given the rising prevalence of painful diabetic neuropathy, it is increasingly important that we understand the best ways to diagnose and treat this condition." | 2.50 | Painful diabetic neuropathy. ( Callaghan, BC; Goutman, SA; Peltier, A, 2014) |
| "Chronic pain is now viewed as a biopsychosocial phenomenon, in which biological, psychological, and social factors are at work." | 2.44 | Practical management strategies for the chronic pain patient. ( Forde, G; Stanos, S, 2007) |
| "This suggests that metabolic syndrome X could be a disorder of the brain due to suboptimal LCPUFAs during perinatal period that triggers low-grade systemic inflammation, implying that perinatal strategies are needed to prevent its development." | 2.44 | Is metabolic syndrome X a disorder of the brain with the initiation of low-grade systemic inflammatory events during the perinatal period? ( Das, UN, 2007) |
| "Persistent hiccups have been reported to occur occasionally during rehabilitation hospitalizations." | 2.44 | Persistent hiccups during rehabilitation hospitalization: three case reports and review of the literature. ( Browne, BA; Schuchmann, JA, 2007) |
| " The highest dosage of GABA yogurt had a greater beneficial effect with respect to insulin resistance than the lower dosages." | 1.56 | Effect of γ-aminobutyric acid-rich yogurt on insulin sensitivity in a mouse model of type 2 diabetes mellitus. ( Chen, L; Li, X; Lu, Y; Lu, Z; Zhu, X, 2020) |
| " There was a dose-response relationship between the above result and the 0." | 1.51 | [γ-aminobutyric acid fortified rice alleviated oxidative stress and pancreatic injury in type 2 diabetic mice]. ( Gao, Q; Jiang, Y; Le, G; Luo, T; Shi, Y; Xu, Y, 2019) |
| "Visual impairment is one of the most feared complications of Type 2 Diabetes Mellitus." | 1.46 | Diabetic brain or retina? Visual psychophysical performance in diabetic patients in relation to GABA levels in occipital cortex. ( Abuhaiba, SI; Castelo-Branco, M; d'Almeida, OC; Gomes, L; Guelho, D; Moreno, C; Quendera, B; Sanches, M, 2017) |
| "Type 2 diabetes mellitus is associated with accelerated cognitive decline." | 1.43 | Increased GABA concentrations in type 2 diabetes mellitus are related to lower cognitive functioning. ( Backes, WH; Edden, RAE; Hofman, PAM; Jansen, JFA; Puts, NAJ; Schram, MT; Stehouwer, CDA; van Boxtel, MPJ; van Bussel, FCG; Wildberger, JE, 2016) |
| "The intensity of tactile allodynia in STZ-induced diabetic mice was alleviated by the oral administration of PGN; however, the antiallodynic effect varied according to its dosing time." | 1.42 | Dosing time-dependent changes in the analgesic effect of pregabalin on diabetic neuropathy in mice. ( Akamine, T; Hashimoto, H; Koyanagi, S; Kusunose, N; Matsunaga, N; Ohdo, S; Taniguchi, M, 2015) |
| " The intensity of tactile allodynia in STZ-induced diabetic mice was alleviated by the oral administration of PGN; however, the antiallodynic effect varied according to its dosing time." | 1.42 | Dosing time-dependent changes in the analgesic effect of pregabalin on diabetic neuropathy in mice. ( Akamine, T; Hashimoto, H; Koyanagi, S; Kusunose, N; Matsunaga, N; Ohdo, S; Taniguchi, M, 2015) |
| "In the type 2 diabetes model GABA levels were increased suggesting that brain glycogen serves a role in maintaining a proper ratio between excitatory and inhibitory neurotransmitters in type 2 diabetes." | 1.38 | Brain glycogen and its role in supporting glutamate and GABA homeostasis in a type 2 diabetes rat model. ( Benie, AJ; Bouman, SD; Schousboe, A; Sickmann, HM; Waagepetersen, HS, 2012) |
| "Gabapentin was restarted at the original dosage and the symptoms resolved within 8 hours." | 1.37 | Akathisia induced by gabapentin withdrawal. ( Hendriks, E; Hsiung, L; See, S, 2011) |
| " Gabapentin was restarted at the original dosage and the symptoms resolved within 8 hours." | 1.37 | Akathisia induced by gabapentin withdrawal. ( Hendriks, E; Hsiung, L; See, S, 2011) |
| "A 76-year-old female with type 2 diabetes was admitted for change in mental status, agitation, and restless limb movements." | 1.37 | Akathisia induced by gabapentin withdrawal. ( Hendriks, E; Hsiung, L; See, S, 2011) |
| "Should the patient experience withdrawal symptoms, the optimal treatment is to restart gabapentin." | 1.37 | Akathisia induced by gabapentin withdrawal. ( Hendriks, E; Hsiung, L; See, S, 2011) |
| "Obesity and type 2 diabetes have reached epidemic proportions; however, scarce information about how these metabolic syndromes influence brain energy and neurotransmitter homeostasis exist." | 1.36 | Obesity and type 2 diabetes in rats are associated with altered brain glycogen and amino-acid homeostasis. ( Benie, AJ; Bouman, SD; Schousboe, A; Sickmann, HM; Waagepetersen, HS, 2010) |
| "Glycogen levels were also lower in this region." | 1.36 | Obesity and type 2 diabetes in rats are associated with altered brain glycogen and amino-acid homeostasis. ( Benie, AJ; Bouman, SD; Schousboe, A; Sickmann, HM; Waagepetersen, HS, 2010) |
| "The basis of the treatment of painful diabetic neuropathy is the use of drugs that block the transmission of pain (antineuritics) and a good metabolic control of underlying disease." | 1.33 | [Intensified insulin therapy plus antineuritic medication is more effective than antineuritics alone in painful diabetic neuropathy]. ( Bastías A, MJ; Olmos C, P; Toro C, L, 2006) |
| "Assessment of pain relief in type 2 diabetes mellitus patients with neuropathic pain treated with gabapentin at daily dose 2400 mg." | 1.32 | [Gabapentin in the treatment of neuropathic pain in patients with type 2 diabetes mellitus]. ( Bilinska, M; Paradowski, B, 2003) |
| "26 patients with type 2 diabetes mellitus and painful neuropathy were included into the study." | 1.32 | [Gabapentin in the treatment of neuropathic pain in patients with type 2 diabetes mellitus]. ( Bilinska, M; Paradowski, B, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.69) | 18.7374 |
| 1990's | 1 (1.69) | 18.2507 |
| 2000's | 13 (22.03) | 29.6817 |
| 2010's | 31 (52.54) | 24.3611 |
| 2020's | 13 (22.03) | 2.80 |
| Authors | Studies |
|---|---|
| Yazdanimoghaddam, F | 1 |
| Ghasemi, M | 1 |
| Teamparvar, H | 1 |
| Soltani, N | 3 |
| Aghaei, M | 1 |
| Rezazadeh, H | 2 |
| Zadhoush, F | 1 |
| Rathwa, N | 1 |
| Parmar, N | 1 |
| Palit, SP | 1 |
| Patel, R | 1 |
| Bhaskaran, RS | 1 |
| Ramachandran, AV | 1 |
| Begum, R | 1 |
| Hagan, DW | 2 |
| Ferreira, SM | 1 |
| Santos, GJ | 1 |
| Phelps, EA | 2 |
| Jiang, X | 1 |
| Liu, K | 1 |
| Jiang, H | 1 |
| Yin, H | 1 |
| Wang, ED | 1 |
| Cheng, H | 1 |
| Yuan, F | 1 |
| Xiao, F | 1 |
| Wang, F | 1 |
| Lu, W | 1 |
| Peng, B | 1 |
| Shu, Y | 1 |
| Li, X | 2 |
| Chen, S | 1 |
| Guo, F | 1 |
| Caramelo, B | 1 |
| Monteiro-Alfredo, T | 1 |
| Martins, J | 1 |
| Sereno, J | 1 |
| Castelhano, J | 1 |
| Manadas, B | 1 |
| Castelo-Branco, M | 3 |
| Matafome, P | 1 |
| Rabinovitch, A | 1 |
| Koshelev, D | 1 |
| Lagunas-Rangel, FA | 1 |
| Kosheleva, L | 1 |
| Gavra, T | 1 |
| Schiöth, HB | 1 |
| Levit, S | 1 |
| Tyurenkov, IN | 1 |
| Faibisovich, TI | 1 |
| Bakulin, DA | 1 |
| Hassanzadeh, S | 1 |
| Bagheri, S | 1 |
| Majid Ahmadi, S | 1 |
| Ahmadi, SA | 1 |
| Moradishibany, I | 1 |
| Dolatkhah, H | 1 |
| Reisi, S | 1 |
| Menegaz, D | 1 |
| Almaça, J | 1 |
| Cianciaruso, C | 1 |
| Rodriguez-Diaz, R | 1 |
| Molina, J | 1 |
| Dolan, RM | 1 |
| Becker, MW | 1 |
| Schwalie, PC | 1 |
| Nano, R | 1 |
| Lebreton, F | 1 |
| Kang, C | 1 |
| Sah, R | 1 |
| Gaisano, HY | 1 |
| Berggren, PO | 1 |
| Baekkeskov, S | 1 |
| Caicedo, A | 1 |
| Chen, L | 1 |
| Zhu, X | 1 |
| Lu, Z | 2 |
| Lu, Y | 1 |
| Gouse, BM | 1 |
| Spears, WE | 1 |
| Nieves Archibald, A | 1 |
| Montalvo, C | 1 |
| d'Almeida, OC | 2 |
| Violante, IR | 1 |
| Quendera, B | 2 |
| Moreno, C | 2 |
| Gomes, L | 2 |
| Jialal, I | 1 |
| Patel, A | 1 |
| Devaraj, S | 1 |
| Adams-Huet, B | 1 |
| Sharifi, MR | 2 |
| Sharifi, M | 2 |
| Hsu, CH | 1 |
| Yu, SM | 1 |
| Lau, SC | 1 |
| Chen, YL | 1 |
| Pei, D | 1 |
| Liu, IC | 1 |
| Sanches, M | 1 |
| Abuhaiba, SI | 1 |
| Guelho, D | 1 |
| Lietzau, G | 2 |
| Darsalia, V | 2 |
| Pintana, H | 2 |
| Östenson, CG | 1 |
| Nyström, T | 2 |
| Fisahn, A | 1 |
| Patrone, C | 2 |
| Sohrabipour, S | 1 |
| Talebi, A | 1 |
| Korol, SV | 1 |
| Jin, Z | 2 |
| Jin, Y | 2 |
| Bhandage, AK | 1 |
| Tengholm, A | 1 |
| Gandasi, NR | 1 |
| Barg, S | 1 |
| Espes, D | 1 |
| Carlsson, PO | 1 |
| Laver, D | 1 |
| Birnir, B | 2 |
| Shin, JS | 1 |
| Kim, JM | 1 |
| Min, BH | 1 |
| Chung, H | 1 |
| Park, CG | 1 |
| Gao, Q | 1 |
| Jiang, Y | 1 |
| Luo, T | 1 |
| Xu, Y | 1 |
| Le, G | 1 |
| Shi, Y | 1 |
| Augestad, IL | 1 |
| Chiazza, F | 1 |
| Thielen, JW | 1 |
| Gancheva, S | 1 |
| Hong, D | 1 |
| Rohani Rankouhi, S | 1 |
| Chen, B | 1 |
| Apostolopoulou, M | 1 |
| Anadol-Schmitz, E | 1 |
| Roden, M | 1 |
| Norris, DG | 1 |
| Tendolkar, I | 1 |
| Kalso, E | 1 |
| Aldington, DJ | 1 |
| Moore, RA | 1 |
| Moreno, E | 1 |
| Vázquez-Polo, FJ | 1 |
| Negrín, MA | 1 |
| Peltier, A | 1 |
| Goutman, SA | 1 |
| Callaghan, BC | 1 |
| Karmakar, S | 1 |
| Rashidian, H | 1 |
| Chan, C | 1 |
| Liu, C | 2 |
| Toth, C | 1 |
| Vinik, A | 1 |
| Rosenstock, J | 1 |
| Sharma, U | 1 |
| Feins, K | 1 |
| Hsu, C | 1 |
| Merante, D | 1 |
| Zhang, H | 1 |
| Pu, Y | 1 |
| Chen, J | 2 |
| Tong, W | 1 |
| Cui, Y | 1 |
| Sun, F | 1 |
| Zheng, Z | 1 |
| Li, Q | 1 |
| Yang, T | 1 |
| Meng, C | 1 |
| Li, L | 1 |
| Yan, Z | 1 |
| Liu, D | 1 |
| Zhu, Z | 1 |
| Akamine, T | 1 |
| Koyanagi, S | 1 |
| Kusunose, N | 1 |
| Hashimoto, H | 1 |
| Taniguchi, M | 1 |
| Matsunaga, N | 1 |
| Ohdo, S | 1 |
| Datusalia, AK | 1 |
| Sharma, SS | 1 |
| van Bussel, FCG | 1 |
| Backes, WH | 1 |
| Hofman, PAM | 1 |
| Puts, NAJ | 1 |
| Edden, RAE | 1 |
| van Boxtel, MPJ | 1 |
| Schram, MT | 1 |
| Stehouwer, CDA | 1 |
| Wildberger, JE | 1 |
| Jansen, JFA | 1 |
| Forde, G | 1 |
| Stanos, S | 1 |
| Sandercock, D | 1 |
| Cramer, M | 1 |
| Wu, J | 1 |
| Chiang, YK | 1 |
| Biton, V | 1 |
| Heritier, M | 1 |
| Al-Salam, S | 1 |
| Hameed, R | 1 |
| Parvez, HS | 1 |
| Adeghate, E | 1 |
| Sickmann, HM | 2 |
| Waagepetersen, HS | 2 |
| Schousboe, A | 2 |
| Benie, AJ | 2 |
| Bouman, SD | 2 |
| Ko, SH | 1 |
| Kwon, HS | 1 |
| Yu, JM | 1 |
| Baik, SH | 1 |
| Park, IB | 1 |
| Lee, JH | 1 |
| Ko, KS | 1 |
| Noh, JH | 1 |
| Kim, DS | 1 |
| Kim, CH | 1 |
| Mok, JO | 1 |
| Park, TS | 1 |
| Son, HS | 1 |
| Cha, BY | 1 |
| Satoh, J | 1 |
| Yagihashi, S | 1 |
| Baba, M | 1 |
| Suzuki, M | 1 |
| Arakawa, A | 1 |
| Yoshiyama, T | 1 |
| Shoji, S | 1 |
| See, S | 1 |
| Hendriks, E | 1 |
| Hsiung, L | 1 |
| Tian, J | 1 |
| Dang, HN | 1 |
| Yong, J | 1 |
| Chui, WS | 1 |
| Dizon, MP | 1 |
| Yaw, CK | 1 |
| Kaufman, DL | 1 |
| Hosseini-Zare, MS | 1 |
| Dashti-Khavidaki, S | 1 |
| Mahdavi-Mazdeh, M | 1 |
| Ahmadi, F | 1 |
| Akrami, S | 1 |
| Taneera, J | 1 |
| Muhammed, SJ | 1 |
| Zhang, E | 1 |
| Lang, S | 1 |
| Salehi, A | 1 |
| Korsgren, O | 1 |
| Renström, E | 1 |
| Groop, L | 1 |
| Braun, M | 1 |
| Ramracheya, R | 1 |
| Rorsman, P | 1 |
| Li, C | 1 |
| Nissim, I | 2 |
| Chen, P | 1 |
| Doliba, N | 1 |
| Zhang, T | 1 |
| Daikhin, Y | 1 |
| Stokes, D | 1 |
| Yudkoff, M | 1 |
| Bennett, MJ | 1 |
| Stanley, CA | 1 |
| Matschinsky, FM | 1 |
| Naji, A | 1 |
| Imam, MU | 1 |
| Ismail, M | 1 |
| Nizeica, V | 1 |
| Collet, P | 1 |
| Marotte, H | 1 |
| Paradowski, B | 1 |
| Bilinska, M | 1 |
| Duarte, AI | 1 |
| Santos, MS | 1 |
| Seiça, R | 2 |
| Oliveira, CR | 1 |
| Laustsen, G | 1 |
| Gilbert, M | 1 |
| Wimett, L | 1 |
| Bastías A, MJ | 1 |
| Toro C, L | 1 |
| Olmos C, P | 1 |
| Das, UN | 1 |
| Schuchmann, JA | 1 |
| Browne, BA | 1 |
| Saravia-Fernandez, F | 1 |
| Faveeuw, C | 1 |
| Blasquez-Bulant, C | 1 |
| Tappaz, M | 1 |
| Throsby, M | 1 |
| Pelletier, G | 1 |
| Vaudry, H | 1 |
| Dardenne, M | 1 |
| Homo-Delarche, F | 1 |
| Duarte, A | 1 |
| Santos, M | 1 |
| Resende de Oliveira, C | 1 |
| Derk, CT | 1 |
| Cynwyd, B | 1 |
| Song, Z | 1 |
| Levin, BE | 1 |
| McArdle, JJ | 1 |
| Bakhos, N | 1 |
| Routh, VH | 1 |
| Azulay, JP | 1 |
| Pouget, J | 1 |
| Goodwin, FK | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of BIODEX Balance System Training on Balance in Type II-diabetic Neuropathy.[NCT04943614] | 88 participants (Actual) | Interventional | 2020-12-01 | Completed | |||
| Diode Laser as a Biomarker for Neuropathic Pain of Peripheral Origin.[NCT06030297] | 301 participants (Anticipated) | Interventional | 2022-11-01 | Recruiting | |||
| A Double-Blind, Placebo Controlled Trial of Intravenous Immunoglobulin Therapy in Patient With Small Fiber Neuropathy Associated With Autoantibodies to TS-HDS and FGFR3[NCT03401073] | Phase 2 | 20 participants (Actual) | Interventional | 2018-09-01 | Completed | ||
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Gabapentin Extended Release (G-ER) Tablets in the Treatment of Patients With Painful Diabetic Peripheral Neuropathy[NCT00712439] | Phase 2 | 147 participants (Actual) | Interventional | 2006-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The Utah Early Neuropathy Scale (UENS) was developed specifically to detect and quantify early small-fiber sensory neuropathy and to recognize modest changes in sensory severity and distribution.~The UENS scale ranges from 0 (no neuropathy) to 42 (severe small fiber neuropathy). The outcome measure is the UENS score from Visit 8 minus the UENS score at visit 1. The difference in the two scores indicates the change in neuropathy severity. A positive value indicates that neuropathy has worsened over the course of the study, a negative value indicates that neuropathy has improved over the course of the study." (NCT03401073)
Timeframe: Visit 1 (time zero) and visit 8 (range of visit time 22-27 weeks after visit 1), thus a total of 22-27 weeks for the study (the range is provided to ensure final follow up is completed despite any conflicts with travel or holidays).
| Intervention | units on a scale (Mean) |
|---|---|
| 0.9% Sodium Chloride | -3.0 |
| Intravenous Immunoglobulin | -1.8 |
"Difference in intra-epidermal nerve fiber density between visits 1 and 8 will be measured.~Intra-epidermal nerve fiber density is a quantitative measure of the number of nerve fibers per millimeter. The outcome is the number of nerve fibers measured at visit 8 minus the number of nerve fibers measured at visit 1. A positive value indicates that nerve fiber density has increased (a better outcome), a negative value indicates that the nerve fiber density has decreased (a worse outcome)." (NCT03401073)
Timeframe: Visit 1 (time zero) and visit 8 (range of visit time 22-27 weeks after visit 1), thus a total of 22-27 weeks for the study (the range is provided to ensure final follow up is completed despite any conflicts with travel or holidays).
| Intervention | fibers/mm (Mean) |
|---|---|
| 0.9% Sodium Chloride | 0.5 |
| Intravenous Immunoglobulin | 0.6 |
"The visual analog scale (VAS) of pain allows for quantification of neuropathic pain.~The VAS pain scale depicts a line ranging from 0 (no pain) to 10 (worst possible pain). The scale is ordinal ranging from 0-10.~The difference in pain between visit 1 and visit 8 (pain measured at visit 8 subtracted from the score at visit 1) is the range. Positive values indicate an increase in pain (worse outcome), negative values indicate an improvement in pain (better outcome)." (NCT03401073)
Timeframe: Visit 1 (time zero) and visit 8 (range of visit time 22-27 weeks after visit 1), thus a total of 22-27 weeks for the study (the range is provided to ensure final follow up is completed despite any conflicts with travel or holidays).
| Intervention | units on a scale (Mean) |
|---|---|
| 0.9% Sodium Chloride | -1.7 |
| Intravenous Immunoglobulin | -1.9 |
6 reviews available for gamma-aminobutyric acid and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
The role of GABA in islet function.
Topics: Adenosine Triphosphate; Autoantigens; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; gamma-Am | 2022 |
Painful diabetic neuropathy.
Topics: Amines; Analgesics; Analgesics, Opioid; Biopsy; Cyclohexanecarboxylic Acids; Diabetes Mellitus, Type | 2014 |
Painful diabetic neuropathy.
Topics: Amines; Analgesics; Analgesics, Opioid; Biopsy; Cyclohexanecarboxylic Acids; Diabetes Mellitus, Type | 2014 |
Painful diabetic neuropathy.
Topics: Amines; Analgesics; Analgesics, Opioid; Biopsy; Cyclohexanecarboxylic Acids; Diabetes Mellitus, Type | 2014 |
Painful diabetic neuropathy.
Topics: Amines; Analgesics; Analgesics, Opioid; Biopsy; Cyclohexanecarboxylic Acids; Diabetes Mellitus, Type | 2014 |
Painful diabetic neuropathy.
Topics: Amines; Analgesics; Analgesics, Opioid; Biopsy; Cyclohexanecarboxylic Acids; Diabetes Mellitus, Type | 2014 |
Painful diabetic neuropathy.
Topics: Amines; Analgesics; Analgesics, Opioid; Biopsy; Cyclohexanecarboxylic Acids; Diabetes Mellitus, Type | 2014 |
Painful diabetic neuropathy.
Topics: Amines; Analgesics; Analgesics, Opioid; Biopsy; Cyclohexanecarboxylic Acids; Diabetes Mellitus, Type | 2014 |
Painful diabetic neuropathy.
Topics: Amines; Analgesics; Analgesics, Opioid; Biopsy; Cyclohexanecarboxylic Acids; Diabetes Mellitus, Type | 2014 |
Painful diabetic neuropathy.
Topics: Amines; Analgesics; Analgesics, Opioid; Biopsy; Cyclohexanecarboxylic Acids; Diabetes Mellitus, Type | 2014 |
Practical management strategies for the chronic pain patient.
Topics: Administration, Cutaneous; Amines; Analgesics; Antidepressive Agents, Tricyclic; Carbamazepine; Chro | 2007 |
Autocrine regulation of insulin secretion.
Topics: Adenosine Triphosphate; Animals; Autocrine Communication; Diabetes Mellitus, Experimental; Diabetes | 2012 |
Is metabolic syndrome X a disorder of the brain with the initiation of low-grade systemic inflammatory events during the perinatal period?
Topics: Animals; Appetite Regulation; Arachidonic Acid; Brain; Diabetes Mellitus, Type 2; Docosahexaenoic Ac | 2007 |
Persistent hiccups during rehabilitation hospitalization: three case reports and review of the literature.
Topics: Aged; Amines; Anti-Anxiety Agents; Anticonvulsants; Cerebral Infarction; Chlorpromazine; Chronic Dis | 2007 |
7 trials available for gamma-aminobutyric acid and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Effectiveness of oral clonidine and gabapentin on peripheral neuropathy in diabetic patients in southwestern Iran: a randomized clinical trial.
Topics: Amines; Analgesics; Clonidine; Cyclohexanecarboxylic Acids; Diabetes Mellitus, Type 2; Diabetic Neur | 2023 |
Investigating the role of neuropathic pain relief in decreasing gait variability in diabetes mellitus patients with neuropathic pain: a randomized, double-blind crossover trial.
Topics: Aged; Analgesics; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Double-Blind | 2014 |
Efficacy and safety of mirogabalin (DS-5565) for the treatment of diabetic peripheral neuropathic pain: a randomized, double-blind, placebo- and active comparator-controlled, adaptive proof-of-concept phase 2 study.
Topics: Adult; Aged; Analgesics; Bridged Bicyclo Compounds; Diabetes Mellitus, Type 1; Diabetes Mellitus, Ty | 2014 |
Gabapentin extended release for the treatment of painful diabetic peripheral neuropathy: efficacy and tolerability in a double-blind, randomized, controlled clinical trial.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Delayed-Action Preparations; Diabetes Mellitus, Typ | 2009 |
Comparison of the efficacy and safety of tramadol/acetaminophen combination therapy and gabapentin in the treatment of painful diabetic neuropathy.
Topics: Acetaminophen; Adult; Aged; Amines; Analgesics, Opioid; Cyclohexanecarboxylic Acids; Diabetes Mellit | 2010 |
Efficacy and safety of pregabalin for treating neuropathic pain associated with diabetic peripheral neuropathy: a 14 week, randomized, double-blind, placebo-controlled trial.
Topics: Analgesics; Asian People; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Neuropathie | 2011 |
Regulation of glucagon secretion in normal and diabetic human islets by γ-hydroxybutyrate and glycine.
Topics: Adult; Diabetes Mellitus, Type 2; Female; gamma-Aminobutyric Acid; Glucagon; Glucagon-Secreting Cell | 2013 |
46 other studies available for gamma-aminobutyric acid and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Long-term GABA administration improves FNDC5, TFAM, and UCP3 mRNA expressions in the skeletal muscle and serum irisin levels in chronic type 2 diabetic rats.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Fibronectins; gamma-Aminobutyri | 2022 |
Calorie restriction potentiates the therapeutic potential of GABA in managing type 2 diabetes in a mouse model.
Topics: Animals; Blood Glucose; Caloric Restriction; Diabetes Mellitus, Experimental; Diabetes Mellitus, Typ | 2022 |
SLC7A14 imports GABA to lysosomes and impairs hepatic insulin sensitivity via inhibiting mTORC2.
Topics: Amino Acids; Animals; Diabetes Mellitus, Type 2; gamma-Aminobutyric Acid; Insulin Resistance; Lysoso | 2023 |
Functional imaging and neurochemistry identify in vivo neuroprotection mechanisms counteracting excitotoxicity and neurovascular changes in the hippocampus and visual cortex of obese and type 2 diabetic animal models.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; gamma-Aminobutyric Acid; Glutam | 2023 |
Efficacy of combination therapy with GABA, a DPP-4i and a PPI as an adjunct to insulin therapy in patients with type 1 diabetes.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase | 2023 |
[Synergistic effects of GABA and hypoglycemic drugs].
Topics: Animals; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; gamma-Aminobutyric Acid; Glu | 2023 |
Mechanism and effects of pulsatile GABA secretion from cytosolic pools in the human beta cell.
Topics: Cytosol; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; gamma-Aminobutyric Acid; Homeostasis; | 2019 |
Effect of γ-aminobutyric acid-rich yogurt on insulin sensitivity in a mouse model of type 2 diabetes mellitus.
Topics: Animals; Blood Glucose; Cholesterol, HDL; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2 | 2020 |
Catatonia in a hospitalized patient with COVID-19 and proposed immune-mediated mechanism.
Topics: Aged; Atrial Fibrillation; Basal Ganglia; Betacoronavirus; C-Reactive Protein; Catatonia; Coronaviru | 2020 |
The neurometabolic profiles of GABA and Glutamate as revealed by proton magnetic resonance spectroscopy in type 1 and type 2 diabetes.
Topics: Aged; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; gamma-Aminobutyric Acid; Glucose | 2020 |
Metabolites that activate the inflammasome in nascent metabolic syndrome.
Topics: Adult; Carnitine; Caspase 1; Diabetes Mellitus, Type 2; gamma-Aminobutyric Acid; Humans; Inflammasom | 2021 |
Gamma-aminobutyric acid attenuates insulin resistance in type 2 diabetic patients and reduces the risk of insulin resistance in their offspring.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Female; GABA Agents; gamma-Aminobutyric Acid; Hum | 2021 |
Restless legs syndrome/Willis-Ekbom disease in type 2 diabetes as the initial manifestation of Parkinson's disease and major cardiovascular disease.
Topics: Aged; Amines; Analgesics; Anticonvulsants; Antihypertensive Agents; Antiparkinson Agents; Aspirin; B | 2017 |
Diabetic brain or retina? Visual psychophysical performance in diabetic patients in relation to GABA levels in occipital cortex.
Topics: Adult; Aged; Brain; Cohort Studies; Diabetes Mellitus, Type 2; Female; gamma-Aminobutyric Acid; Huma | 2017 |
Type 2 diabetes alters hippocampal gamma oscillations: A potential mechanism behind impaired cognition.
Topics: Animals; Cognition; Cognitive Dysfunction; Diabetes Mellitus, Type 2; Disease Models, Animal; Gamma | 2017 |
GABA dramatically improves glucose tolerance in streptozotocin-induced diabetic rats fed with high-fat diet.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; | 2018 |
Functional Characterization of Native, High-Affinity GABA
Topics: Diabetes Mellitus, Type 2; Exocytosis; gamma-Aminobutyric Acid; Humans; Insulin; Insulin-Secreting C | 2018 |
Absence of spontaneous regeneration of endogenous pancreatic β-cells after chemical-induced diabetes and no effect of GABA on α-to-β cell transdifferentiation in rhesus monkeys.
Topics: Animals; Cell Transdifferentiation; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; gamm | 2019 |
[γ-aminobutyric acid fortified rice alleviated oxidative stress and pancreatic injury in type 2 diabetic mice].
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; GABA Agents; gam | 2019 |
Obesity-induced type 2 diabetes impairs neurological recovery after stroke in correlation with decreased neurogenesis and persistent atrophy of parvalbumin-positive interneurons.
Topics: Age Factors; Animals; Atrophy; Brain; Diabetes Mellitus, Type 2; Disease Models, Animal; gamma-Amino | 2019 |
Higher GABA concentration in the medial prefrontal cortex of Type 2 diabetes patients is associated with episodic memory dysfunction.
Topics: Adult; Diabetes Mellitus, Type 2; Female; gamma-Aminobutyric Acid; Humans; Magnetic Resonance Spectr | 2019 |
Drugs for neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetes Mellitus, Type 2; Diabetic Neuropathies; D | 2013 |
Objective Bayesian meta-analysis for sparse discrete data.
Topics: Bayes Theorem; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetes, Gestational; Epilepsy; | 2014 |
Gastrointestinal intervention ameliorates high blood pressure through antagonizing overdrive of the sympathetic nerve in hypertensive patients and rats.
Topics: Adult; Animals; Biomarkers; Blood Pressure; Cardiovascular System; Cold-Shock Response; Diabetes Mel | 2014 |
Dosing time-dependent changes in the analgesic effect of pregabalin on diabetic neuropathy in mice.
Topics: Analgesics; Animals; Calcium Channels; Carrier Proteins; Circadian Rhythm; Diabetes Mellitus, Type 1 | 2015 |
NF-κB Inhibition Resolves Cognitive Deficits in Experimental Type 2 Diabetes Mellitus through CREB and Glutamate/GABA Neurotransmitters Pathway.
Topics: Animals; Avoidance Learning; Blood Glucose; Brain; Cognition Disorders; CREB-Binding Protein; Diabet | 2016 |
Increased GABA concentrations in type 2 diabetes mellitus are related to lower cognitive functioning.
Topics: Aged; Blood Glucose; Case-Control Studies; Cognition; Cognitive Dysfunction; Diabetes Mellitus, Type | 2016 |
Diabetes mellitus decreases the expression of calcitonin-gene related peptide, gamma-amino butyric acid and glutamic acid decarboxylase in human pancreatic islet cells.
Topics: Calcitonin Gene-Related Peptide; Diabetes Mellitus, Type 2; Fluorescent Antibody Technique; gamma-Am | 2009 |
Obesity and type 2 diabetes in rats are associated with altered brain glycogen and amino-acid homeostasis.
Topics: Alanine; Amino Acids; Animals; Aspartic Acid; Blood Glucose; Brain; Diabetes Mellitus, Type 2; gamma | 2010 |
Akathisia induced by gabapentin withdrawal.
Topics: Aged; Akathisia, Drug-Induced; Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetes Mellitus, T | 2011 |
Oral treatment with γ-aminobutyric acid improves glucose tolerance and insulin sensitivity by inhibiting inflammation in high fat diet-fed mice.
Topics: Administration, Oral; Animals; CD4-Positive T-Lymphocytes; Diabetes Mellitus, Type 2; Diet, High-Fat | 2011 |
Brain glycogen and its role in supporting glutamate and GABA homeostasis in a type 2 diabetes rat model.
Topics: Animals; Aspartic Acid; Brain Chemistry; Cerebral Cortex; Diabetes Mellitus, Type 2; gamma-Aminobuty | 2012 |
Peripheral neuropathy response to erythropoietin in type 2 diabetic patients with mild to moderate renal failure.
Topics: Aged; Aged, 80 and over; Amines; Cyclohexanecarboxylic Acids; Diabetes Mellitus, Type 2; Diabetic Ne | 2012 |
γ-Aminobutyric acid (GABA) signalling in human pancreatic islets is altered in type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Disease Progression; Dose-Response Relationship, Drug; Down-Regulation; F | 2012 |
Nutrigenomic effects of germinated brown rice and its bioactives on hepatic gluconeogenic genes in type 2 diabetic rats and HEPG2 cells.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; gamma-Aminobutyric Acid; Gene Expres | 2013 |
Bortezomib induced a phrenic palsy in a multiple myeloma patient.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Boronic Acid | 2013 |
[Gabapentin in the treatment of neuropathic pain in patients with type 2 diabetes mellitus].
Topics: Acetates; Aged; Amines; Calcium Channel Blockers; Cyclohexanecarboxylic Acids; Diabetes Mellitus, Ty | 2003 |
Oxidative stress affects synaptosomal gamma-aminobutyric acid and glutamate transport in diabetic rats: the role of insulin.
Topics: Animals; Biological Transport; Cerebral Cortex; Diabetes Mellitus, Type 2; gamma-Aminobutyric Acid; | 2004 |
A look back at the most influential drug approvals of 2005.
Topics: Amyloid; Analgesics; Anticonvulsants; Antiparkinson Agents; Diabetes Mellitus, Type 2; Diphtheria-Te | 2006 |
[Intensified insulin therapy plus antineuritic medication is more effective than antineuritics alone in painful diabetic neuropathy].
Topics: Adrenergic Uptake Inhibitors; Adult; Aged; Amines; Analgesics; Clomipramine; Cyclohexanecarboxylic A | 2006 |
Localization of gamma-aminobutyric acid and glutamic acid decarboxylase in the pancreas of the nonobese diabetic mouse.
Topics: Animals; Antibodies, Monoclonal; Diabetes Mellitus, Type 2; Female; gamma-Aminobutyric Acid; Glutama | 1996 |
Effect of oxidative stress on the uptake of GABA and glutamate in synaptosomes isolated from diabetic rat brain.
Topics: Animals; Ascorbic Acid; Blood Glucose; Body Weight; Brain; Diabetes Mellitus, Type 2; Disease Models | 2000 |
Malignant appearing cachexia in an older patient with Bruns-Garland syndrome.
Topics: Acetates; Aged; Amines; Analgesics; Cachexia; Cyclohexanecarboxylic Acids; Diabetes Mellitus, Type 2 | 2000 |
Convergence of pre- and postsynaptic influences on glucosensing neurons in the ventromedial hypothalamic nucleus.
Topics: Adenosine Triphosphate; Animals; Cell Count; Diabetes Mellitus, Type 2; Diet; gamma-Aminobutyric Aci | 2001 |
[Diabetic neuropathies].
Topics: Acetates; Amines; Animals; Anti-Inflammatory Agents, Non-Steroidal; Carbamazepine; Controlled Clinic | 2001 |
From the Alcohol, Drug Abuse, and Mental Health Administration.
Topics: Diabetes Mellitus, Type 2; Ethanol; Female; Fetal Growth Retardation; gamma-Aminobutyric Acid; Human | 1989 |